Xin Lang Zheng Quan·2025-08-25 04:16Core Viewpoint - Nocera Biopharma's stock has experienced significant fluctuations, with a year-to-date increase of 141.86% but a recent decline of 11.37% over the past five trading days [1] Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and minimal contributions from testing and R&D services [2] - As of June 30, 2025, Nocera Biopharma reported a revenue of 731 million yuan, reflecting a year-on-year growth of 74.26%, while the net profit attributable to shareholders was -30.09 million yuan, an increase of 88.51% year-on-year [2] Stock Performance and Trading Activity - As of August 25, Nocera Biopharma's stock price was 29.70 yuan per share, with a market capitalization of 52.41 billion yuan [1] - The stock has seen a trading volume of 160 million yuan, with a turnover rate of 1.97% [1] - The net outflow of main funds was 29.45 million yuan, with large orders showing a buy of 31.01 million yuan and a sell of 39.06 million yuan [1] Shareholder Composition - As of June 30, 2025, the number of shareholders increased by 13.80% to 15,200 [2] - Notable institutional shareholders include China Europe Medical Health Mixed A and others, with varying changes in their holdings [3]